WallStreetZenWallStreetZen

NASDAQ: ACAD
Acadia Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ACAD past revenue growth

How has ACAD's revenue growth performed historically?
Company
40.45%
Industry
145.73%
Market
17.2%
ACAD's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ACAD's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ACAD's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ACAD earnings and revenue history

Current Revenue
$726.4M
Current Earnings
-$61.3M
Current Profit Margin
-8.4%

ACAD Return on Equity

Current Company
-15.7%
Current Industry
-63.5%
Current Market
188%
ACAD's Return on Equity (-15.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ACAD announces earnings.

ACAD Return on Assets

Current Company
-9.1%
Current Industry
2.9%
ACAD is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ACAD Return on Capital Employed

Current Company
-10.32%
Current Industry
19.5%
ACAD has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ACAD vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ACAD$726.44M-$45.48M-$61.29M+26.55%N/A
MLTX$0.00-$43.97M-$44.08MN/AN/A
ARWR$181.74M-$262.45M-$296.81M+30.90%N/A
ACLX$110.32M-$44.26M-$70.69MN/AN/A
MOR$259.00M-$41.75M-$206.23M+24.68%N/A
View Top Biotech Stocks

ACAD earnings dates

Next earnings date
May 6, 2024

Acadia Pharmaceuticals Earnings & Revenue FAQ

What were ACAD's earnings last quarter?

On Invalid Date, Acadia Pharmaceuticals (NASDAQ: ACAD) reported Q4 2023 earnings per share (EPS) of $0.28, up 207.69% year over year. Total Acadia Pharmaceuticals earnings for the quarter were $45.80 million. In the same quarter last year, Acadia Pharmaceuticals's earnings per share (EPS) was -$0.26.

If you're new to stock investing, here's how to buy Acadia Pharmaceuticals stock.

What was ACAD's earnings growth in the past year?

As of Q2 2024, Acadia Pharmaceuticals's earnings has grown year over year. Acadia Pharmaceuticals's earnings in the past year totalled -$61.29 million.

What is ACAD's earnings date?

Acadia Pharmaceuticals's earnings date is Invalid Date. Add ACAD to your watchlist to be reminded of ACAD's next earnings announcement.

What was ACAD's revenue last quarter?

On Invalid Date, Acadia Pharmaceuticals (NASDAQ: ACAD) reported Q4 2023 revenue of $231.04 million up 69.27% year over year. In the same quarter last year, Acadia Pharmaceuticals's revenue was $136.49 million.

What was ACAD's revenue growth in the past year?

As of Q2 2024, Acadia Pharmaceuticals's revenue has grown 40.45% year over year. This is 105.29 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Acadia Pharmaceuticals's revenue in the past year totalled $726.44 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.